Search Result

Results for "

FAK+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (12) Autophagy (1) Bcl-2 Family (1) Caspase (2) COX (1) Cytochrome P450 (1) EGFR (1) ERK (1) FAK (47) FLT3 (1) Hippo (MST) (1) Isotope-Labeled Compounds (1) Ligands for Target Protein for PROTAC (1) Lipoxygenase (1) PROTACs (1) Pyk2 (1) Raf (1) Reactive Oxygen Species (ROS) (1) Reference Standards (3) Src (1) YAP (1)
By Research Areas:	Cancer (47) Neurological Disease (2)

Inhibitors & Agonists

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12289

Defactinib Maximum Cited Publications 57 Publications Verification VS-6063; PF-04554878	FAK	Cancer
Defactinib (VS-6063; PF-04554878) is a novel *FAK* inhibitor with potential antiangiogenic and antineoplastic activities.

HY-10461

PF-573228 30+ Cited Publications	FAK Apoptosis	Cancer
PF-573228 is a potent and selective *FAK* inhibitor with IC₅₀ of 4 nM for purified recombinant catalytic fragment of FAK.

HY-12444

Y15 25+ Cited Publications FAK Inhibitor 14	FAK	Cancer
Y15 is a potent and specific inhibitor of focal adhesion kinase (FAK) that inhibits its autophosphorylation activity, decreases the viability of cancer cells, and blocks tumor growth.

HY-122844

Ifebemtinib 3 Publications Verification BI-853520; IN-10018	FAK	Cancer
Ifebemtinib (BI 853520) is an orally active and potent focal adhesion kinase (FAK) inhibitor (recombinant FAK IC₅₀=1 nM). Ifebemtinib shows anti-proliferative activity against cancer cells. Ifebemtinib inhibits FER Kinase and FES Kinase with IC₅₀s of 900 nM and 1040 nM, respectively .

HY-12289A

Defactinib hydrochloride Maximum Cited Publications 57 Publications Verification VS-6063 hydrochloride; PF 04554878 hydrochloride	FAK	Cancer
Defactinib hydrochloride (VS-6063 hydrochloride; PF 04554878 hydrochloride) is a novel *FAK* inhibitor, which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.

HY-132296

GSK215 2 Publications Verification	FAK PROTACs	Cancer
GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader with a pDC₅₀ of 8.4. GSK215 is designed by a binder for the VHL E3 ligase and the FAK inhibitor VS-4718. GSK215 induces rapid and prolonged FAK degradation, giving a long-lasting effect on FAK levels and a marked pharmacokinetic/pharmacodynamics (PK/PD) disconnect .

HY-144448

FAK-IN-2 1 Publications Verification	FAK Apoptosis	Cancer
FAK-IN-2 is a potent and orally active focal adhesion kinase (FAK) inhibitor, with anticancer activity (FAK IC₅₀= 35 nM). FAK-IN-2 covalently inhibits the autophosphorylation of FAK in a dose-dependent manner, and inhibits the clone formation and migration of tumor cells, inducing apoptosis .

HY-148070

FLT3-IN-17	FLT3 FAK Cytochrome P450	Cancer
FLT3-IN-17 inhibits CYPs and FLT3 mutants activity (IC₅₀s: <0.5 nM for D835Y). FLT3-IN-17 is also a *FAK* inhibitor, with an IC₅₀ value of 12 nM. FLT3 ligand-2 can be used in the research of cancers .

HY-122844A

Ifebemtinib hydrochloride 3 Publications Verification BI-853520 hydrochloride; IN-10018 hydrochloride	FAK	Cancer
Ifebemtinib (BI-853520) hydrochloride is an orally active and potent focal adhesion kinase (FAK) inhibitor (IC₅₀ = 1 nM for recombinant FAK). Ifebemtinib hydrochloride exhibits antiproliferative activity against cancer cells .

HY-155439

FAK-IN-14	FAK	Cancer
FAK-IN-14 (compound 8d) is a focal adhesion kinase(FAK) inhibitor with an IC₅₀ value of 0.2438 nM. FAK-IN-14 induces U87-MG cell early apoptosis and arrest the cell at the G2/M phase .

HY-145108

FAK-IN-1	FAK	Cancer
FAK-IN-1 is a *FAK* inhibitor with anticancer activities (WO2020231726 (Example 27)) .

HY-100498A

GSK-2256098 hydrochloride 5+ Cited Publications	FAK Apoptosis	Cancer
GSK-2256098 hydrochloride is a focal adhesion kinase (FAK) inhibitor that exhibits potential antiangiogenic and antineoplastic activities. GSK-2256098 hydrochloride targets FAK to inhibit tumor cell growth by regulating cell adhesion, migration, proliferation, and survival.

HY-128580

FAK inhibitor 2 2 Publications Verification	FAK	Cancer
FAK inhibitor 2 is a potent focal adhesion kinase (FAK) inhibitor with an IC₅₀  of 0.07 nM, with antitumor and anti-angiogenesis activities .

HY-148109

FAK-IN-7	FAK	Cancer
FAK-IN-7 (compound 5r) is a *FAK* inhibitor (IC₅₀=11.72 µM). FAK-IN-7 has good anti-proliferative activity and can be used in cancer research .

HY-146065

FAK-IN-4	FAK Apoptosis	Cancer
FAK-IN-4 (Compound 7d) is potential *FAK* inhibitor with anticancer activities. FAK-IN-4 induces cell apoptosis .

HY-12289S

Defactinib-d6 VS-6063-d₆; PF-04554878-d₆	FAK Isotope-Labeled Compounds	Cancer
Defactinib-d6 is a deuterium labeled Defactinib (HY-12289). Defactinib is a novel *FAK* inhibitor with potential antiangiogenic and antineoplastic activities .

HY-12289R

Defactinib (Standard) VS-6063 (Standard); PF-04554878 (Standard)	FAK Reference Standards	Cancer
Defactinib (Standard) is the analytical standard of Defactinib. This product is intended for research and analytical applications. Defactinib (VS-6063; PF-04554878) is a novel FAK inhibitor with potential antiangiogenic and antineoplastic activities.

HY-178969

GZD-257	FAK Pyk2 Apoptosis	Neurological Disease Cancer
GZD-257 is a brain-penetrant, ATP-competitive *FAK* inhibitor (IC₅₀ = 14.3 nM), performing 4.77-fold selectivity with FAK to Pyk2 (IC₅₀ = 68.2 nM). GZD-257 can significantly induce apoptosis of U118MG cells and arrest the cell cycle at the G2/M phase. GZD-257 can be used for the study of Glioblastoma (GBM) .

HY-18928

FAK inhibitor 5	FAK	Cancer
FAK inhibitor 5 (compound 2) is a novel allosteric *FAK* inhibitor, with IC₅₀ values in the low micromolar range .

HY-117836

FAK-IN-16	FAK	Cancer
FAK-IN-16 (compound OXA-11) is an orally active, selective focal adhesion kinase (FAK) inhibitor with an IC₅₀ of 1.2 pM. FAK-IN-16 inhibits FAK phosphorylation at pFAK[Y397] and pFAK[Y861]. FAK-IN-16 slows tumor growth and reduces tumor vascularity, invasion. FAK-IN-16 potentiates effects of Cisplatin (HY-17394) on tumor cell proliferation and apoptosis in vitro and anti-tumor actions in mice .

HY-162879

FAK inhibitor 7	FAK Src Akt Autophagy	Cancer
FAK inhibitor 7 is a type of *FAK* inhibitor with an IC₅₀ value of 3.58 nM. FAK inhibitor 7 can inhibit the downstream signaling cascades of FAK (like Src and AKT), causing ovarian cancer cells to stall in the G0/G1 phase and induce cytotoxic autophagy. FAK inhibitor 7 can also suppress tumor metastasis and growth in ovarian cancer mice .

HY-116497

PH11	FAK	Cancer
PH11 is a novel focal adhesion kinase (FAK) inhibitor that rapidly induces apoptosis in TRAIL-resistant PANC-1 cells when combined with TRAIL, but has no effect on normal human fibroblasts. The study found that PH11 downregulates c-FLIP through inhibition of FAK and phosphatidylinositol-3-kinase (PI3K)/AKT pathways, thereby restoring the TRAIL apoptotic pathway, suggesting that this combination therapy may provide an attractive therapeutic strategy for the safe and effective treatment of pancreatic cancer. PH11 selectively inhibits c-FLIP expression by modulating upstream signaling pathways and may represent an innovative therapeutic strategy. Although further work is needed to fully elucidate the mechanism of PH11-induced TRAIL sensitization, we believe that our results will provide a new approach to target c-FLIP without the risk of interfering with caspase-8 processing, which could potentially lead to TRAIL resistance. This study also suggests a role for the FAK/AKT signaling pathway in regulating c-FLIP expression in TRAIL-induced apoptosis, and this understanding will provide important clues to control the resistance mechanism to optimize the potential of TRAIL-based pancreatic cancer treatment.

HY-146203

FAK inhibitor 6	FAK	Cancer
Compound 26F not only optimized the effective inhibitory enzyme (ic₅₀= 28.2 nm), but also showed relatively less cytotoxicity (ic₅₀= 3.32 μ M) And induced MDA-MB-231 cell apoptosis in a dose-dependent manner, effectively blocking MDA-MB-231 cells in g0/g1 phase.

HY-149259

FAK-IN-9	FAK	Cancer
FAK-IN-9 (Compound 8f) is a potent and orally active *FAK* inhibitor with an IC₅₀ of 27.44 nM. FAK-IN-9 induces triple-negative breast cancer (TNBC) cell apoptosis .

HY-148110

FAK-IN-8	FAK	Cancer
FAK-IN-8 (compound 5h) is a *FAK* inhibitor (IC₅₀=5.32 µM). FAK-IN-8 has good anti-proliferative activity and can be used in cancer research .

HY-162034

FAK-IN-17	FAK	Cancer
FAK-IN-17 is a focal adhesion kinase (FAK) inhibitor. FAK-IN-17 possesses anticancer activity against A549 and MDA-MB-231 cell lines with IC₅₀ values of 130 nM and 94 nM .

HY-169319

FAK-IN-21	FAK	Cancer
FAK-IN-21 (compound 9) is a *FAK* inhibitor with the IC₅₀ of 37.52 nM. FAK-IN-21 inhibits cell growth and the phosphorylation of FAK. FAK-IN-21 can be used for study of diffuse gastric cancer .

HY-10461R

PF-573228 (Standard)	Reference Standards FAK Apoptosis	Cancer
PF-573228 (Standard) is the analytical standard of PF-573228. This product is intended for research and analytical applications. PF-573228 is a potent and selective FAK inhibitor with IC50 of 4 nM for purified recombinant catalytic fragment of FAK.

HY-12289AR

Defactinib hydrochloride (Standard) VS-6063 hydrochloride (Standard); PF 04554878 hydrochloride (Standard)	FAK Reference Standards	Cancer
Defactinib (hydrochloride) (Standard) is the analytical standard of Defactinib (hydrochloride). This product is intended for research and analytical applications. Defactinib hydrochloride (VS-6063 hydrochloride; PF 04554878 hydrochloride) is a novel FAK inhibitor, which inhibits FAK phosphorylation at the Tyr397 site in a time- and dose-dependent manner.

HY-150730

FAK-IN-6	FAK	Cancer
FAK-IN-6 is a potent *FAK* inhibitor with an IC₅₀ value of 1.415 nM. FAK-IN-6 has anti-proliferative activity against certain cancer cell lines. FAK-IN-6 can be used for researching pancreatic cancer .

HY-173603

FAK-IN-27	FAK	Cancer
FAK-IN-27 (compound 8A) is a potent and selective *FAK* inhibitor with an IC₅₀ of 4.968 nM. FAK-IN-27 suppresses H1299 cells proliferation with an IC₅₀ of 0.28 μM. FAK-IN-27 can be used in the study of NSCLC .

HY-155440

FAK-IN-15	FAK	Cancer
FAK-IN-15 (Compound 9b) is a focal adhesion kinase (FAK) inhibitor with an IC₅₀ value of 0.2691 nM. FAK-IN-15 has anti-tumor activity with an IC₅₀ value of 1.033 μM against U87-MG cells .

HY-173495

FAK-IN-25	FAK Apoptosis	Cancer
FAK-IN-25 (4c) is a *FAK* inhibitor with an IC₅₀ of 50.98 nM. FAK-IN-25 (4c) induces apoptosis and causes cell cycle arrest at G1 phase. FAK-IN-25 (4c) can be used in cancer research .

HY-156334

FAK-IN-12	FAK	Cancer
FAK-IN-12 (Compound 12S) is a *FAK* inhibitor (IC₅₀ = 47 nM). FAK-IN-12 inhibits MGC-803, HCT-116 and KYSE30 cell proliferation (IC₅₀: 0.24, 0.45, 0.44 μM). FAK-IN-12 induces apoptosis and cellular senescence .

HY-170936

MY-1576	FAK Hippo (MST) YAP	Cancer
MY-1576 is a *FAK* inhibitor with an IC₅₀ of 8 nM. MY-1576 can activate the Hippo pathway, thereby blocking the regulation of YAP/TAZ. MY-1576 also effectively inhibits tumor growth in the KYSE30 xenograft mouse model, demonstrating good safety, and effectively downregulates the autophosphorylation of FAK and the levels of YAP/TAZ in vivo .

HY-156026

FAK-IN-11	FAK	Cancer
FAK-IN-11 (Compound 4l) is a *FAK* inhibitor. FAK-IN-11 binds to the ATP binding pocket of FAK, and inhibits phosphorylation of FAK protein. FAK-IN-11 shows cytotoxic activity against the MDA-MB-231 cells with an IC₅₀ of 13.73? μM. FAK-IN-11 induces non-apoptotic cell death in MDA-MB-231 cells .

HY-163715

Antitumor agent-165	FAK	Cancer
Antitumor agent-165 (Compound 10l) is a potent focal adhesion kinase (FAK) inhibitor. Antitumor agent-165 exhibits effective antiproliferative activity against CAPAN-1, PANC-1, PATU-T, SUIT-2, BxPC-3, PDAC-3 and PANC-1 GR with IC₅₀s in the range of 1.04-3.44 μM .

HY-173515

FAK-IN-26	FAK	Cancer
FAK-IN-26 is a BBB-penetrable Focal Adhesion Kinase (FAK) inhibitor (IC₅₀: 0.87 nM). FAK-IN-26 significantly suppresses tumor cell viability, cancer stem cell activity, and cell migration in A549 and SKOV-3 cell lines. FAK-IN-26 has potent anti-cancer activity in A549 and SKOV-3 tumor mice models with tumor inhibition rates of 59.15 % and 57.9 % .

HY-168899

FAK-IN-24	FAK Apoptosis	Cancer
FAK-IN-24 (Compound 9f) is a *FAK* inhibitor (IC₅₀: 0.815 nM). FAK-IN-24 induces DNA damage and apoptosis. FAK-IN-24 has anti-glioblastoma activity. FAK-IN-24 inhibits proliferation of glioblastoma cell lines U87-MG (IC₅₀ = 15 nM) and U251 (IC₅₀ = 20 nM). FAK-IN-24 inhibits tumor growth in U87-MG xenograft model .

HY-175039

FAK-IN-28	FAK Apoptosis Reactive Oxygen Species (ROS) Caspase	Cancer
FAK-IN-28 is an orally active *FAK* inhibitor (IC₅₀ = 0.4 nM). FAK-IN-28 exhibits dual antiproliferative and anti-metastatic properties. FAK-IN-28 triggers caspase-3-dependent apoptosis via ROS elevation. FAK-IN-28 inhibits tumor growth without causing weight loss or hepatotoxicity. FAK-IN-28 is useful in the study of FAK-driven malignancies, such as colon cancer, cervical cancer, triple-negative breast cancer, and melanoma .

HY-160411

FAK-IN-18	FAK	Cancer
FAK-IN-18 is a focal adhesion kinase (FAK) inhibitor with an IC₅₀ of .84 nM. FAK-IN-18 can be used for the research of gastric cancer .

HY-183697

FAK-IN-30	FAK	Cancer
FAK-IN-30 is a focal adhesion kinase (FAK) inhibitor with moderate cytotoxicity against breast cancer cells. FAK-IN-30 can be used for the research of triple-negative breast cancer .

HY-183946

NVP-TAC544	FAK	Cancer
NVP-TAC544 is a focal adhesion kinase (FAK) inhibitor. NVP-TAC544 inhibits angiogenesis. NVP-TAC544 can be used for the research of melanoma (primary or metastatic) .

HY-179679

FAK-IN-29	FAK Apoptosis	Cancer
FAK-IN-29 is a selective *FAK* inhibitor with an IC₅₀ of 0.5 nM. FAK-IN-29 can inhibit the proliferation and colony formation of MDA-MB-231 cells, and induce cell cycle arrest and apoptosis. FAK-IN-29 exhibits antitumor activity and can be used for the research of tumors such as triple-negative breast cancer .

HY-183769

FAK-IN-31	FAK Ligands for Target Protein for PROTAC	Cancer
FAK-IN-31 is a *FAK* inhibitor with antiproliferative activity against a variety of cancer cell lines. FAK-IN-31 serves as a PROTAC target protein ligand for the development of FAK-targeted PROTAC degrader heads, such as PROTAC FAK degrader 5 (HY-183768). FAK-IN-31 can be used in the research of colorectal cancer, pancreatic cancer, breast cancer, hepatocellular carcinoma and lung cancer .

HY-183284

GZD-552	FAK ERK Apoptosis	Neurological Disease Cancer
GZD-552 is a potent orally active *FAK* inhibitor with a human FAK IC₅₀ of 5.8 nM. GZD-552 suppresses FAK phosphorylation activation and downstream ERK signaling. GZD-552 induces apoptosis and G₂/M cell cycle arrest, and exhibits antiproliferative activities in glioblastoma multiforme cells. GZD-552 exhibits antitumor efficacy in mice xenograft model. GZD-552 can be used for the research of glioblastoma multiforme .

HY-181061

COX/5-LO-IN-2	COX EGFR Lipoxygenase FAK Raf Apoptosis Caspase Bcl-2 Family	Cancer
COX/5-LO-IN-2 is a COX2, EGFR, COX1, 5-LOX, BRAF and *FAK* inhibitor with IC₅₀ of 1.22 μM, 2.5 μM, 2.95 μM, 4.65 μM, 7.4 μM, 12.2 μM, respectively. COX/5-LO-IN-2 induces cell growth arrest at G2/M phase. COX/5-LO-IN-2 triggers apoptotic activity by up-regulating proapoptotic proteins p53, Bax, and caspase-7 and down-regulating anti-apoptotic protein Bcl-2. COX/5-LO-IN-2 can be used for the research of breast cancer .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: